GlassScriptPhysician profile
Breta D Boots
NPI 1891080255
$6,208.35
in general payments reported to CMS, 2019-2025
44 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $591 · 2021: $388 · 2022: $732 · 2023: $1,111 · 2024: $911 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.73 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,674.15 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Supernus Pharmaceuticals, INC. | $455.32 | 2019-2020 | |
| Eisai INC. | $388.18 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $312.93 | 2019-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $299.86 | 2019-2024 | Austedo Xr |
| Allergan, INC. | $288.69 | 2019-2022 | |
| Lilly USA, LLC | $284.58 | 2019-2025 | Kisunla, Amyvid |
| Pfizer INC. | $227.31 | 2023-2025 | |
| Ucb, INC. | $203.23 | 2019-2020 | |
| Amgen INC. | $181.43 | 2019-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $167.02 | 2022 | |
| Vanda Pharmaceuticals INC. | $118.86 | 2019 | |
| Mdd US Operations, LLC | $98.11 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $97.57 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $90.69 | 2022-2023 | Trudhesa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breta Boots listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.